Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

ria, Czech Republic, Belarus, Bosnia, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Monaco, Netherlands, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Spain (co-promotion with BIAL from launch) Sweden, Switzerland, Turkey, Ukraine and United Kingdom.

About epilepsy, partial-onset seizures and their treatment

Epilepsy is one of the most common neurological diseases, affecting approximately 1 in 100 people(6).

Epilepsy is a chronic neurological disease characterised by abnormal discharges of neuronal activity causing seizures. Clinically, these manifest as convulsions or jerking of muscles. Depending on the seizure type, seizures may be limited to one part of the body, or may be generalised to involve the whole body. Patients may also experience abnormal sensations, altered behaviour or altered consciousness. Epilepsy is a disorder with many possible causes. Often the cause of epilepsy is unknown. However, anything that disturbs the normal pattern of neurone activity - from illness to brain damage to abnormal brain development, can lead to seizures.

Epilepsy is characterised by abnormal firing of impulses from nerve cells in the brain. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more generalised; the symptoms vary according to the affected areas. Nerve impulses are triggered via voltage-gated sodium channels in the nerve cell membrane.

Treatment of partial-onset seizures, the most common type of epilepsy, presents a constant challenge - up to 40% of patients with partial-onset seizures do not achieve seizure control with current anti-epileptic drugs(2).

Furthermore, adverse events, such as lightheadedness (dizziness), somnolence (sleepiness), and cognitive slowing, are
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),...overing,developingandcommercializingnoveldrugstotr...iscalyearendedSeptember30,2009.AtSeptember30,2009P...shortterminvestments. ,, PipelineUpdateand2009...,, InlateNovember2009,anindependentDataMonitori...
(Date:11/25/2009)...PRNewswire-FirstCall/--Formanyofthemillionsofheari...thuntreated hearingloss ,theholidaysmaynotbealltha...eniorvicepresidentofHearUSA(Amex: EAR ),oneofAmeri...idstudieshavelinkedhearinglosstostress,frustration...holidaygatheringswithfamiliesandfriends,whenmanyof...
(Date:11/25/2009)...--Reportlinker.comannouncesthatanewmarketresearchr...sDentalDevicesMarketAnalysisandForecaststo2015 ,...tates-Dental-Devices-Market-Analysis-and-Forecasts...etAnalysisandForecaststo2015 ,, Summary ,,...onanddatarelatingtotheUSdentaldevicesmarket.Italso...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Elsevier Announces 2008 Journal Impact Factor Highlights 50255 1Elsevier Announces 2008 Journal Impact Factor Highlights 50255 2Elsevier Announces 2008 Journal Impact Factor Highlights 50255 3Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 1Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 2Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 3
...007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) tod...tudy of Proellex in the treatment of,endometriosis...menopausal women and has completed six months of d...ellex(TM) as well as a,positive control arm. The p... known as Lupron(R) or leuprolide acetate, commonl...
...- Accera, Inc.,today is presenting data from an op... of AC-1202 (Ketasyn) in Alzheimer,s disease (AD),...ference on,Prevention of Dementia in Washington, D...al and preclinical studies, AC-1202 was,shown to b...,cognition of subjects of a particular pharmacogen...
Other Medicine Technology:Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leadin... today announced the expansion of its services to ... Dr. Doug Macmillan. , ... pleased to announce that Dr. Doug Macmillan, an e... an additional advanced training seminar. RTDenta...
(Date:11/25/2009)...lif.,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceu...panywillhosttwoinvestoreventsinDecember: ,, A...00a.m.ET ,, Principalinvestigatorswilldiscuss...nd/orrefractorymultiplemyeloma,asfeaturedatthe51st...positioninNewOrleans,LA.Theteleconferencewillbegin...
(Date:11/25/2009)...v.25/PRNewswire-USNewswire/--TheBlackAIDSInstitute...cutiveleadershipfor2010. ,, ThenewBoardMembersa...licpolicy,law,finance,governmenthealthprograms,edi...esfromawiderangeofpersonalbackgroundsincludingboth...IVthemselves,andrepresentingmultipleagegroups. ,...
(Date:11/25/2009)...overy that grew out of a collaboration between UCL... hope to the nearly 10 million Americans who suffe...nown as hardening of the arteries, peripheral arte...lem in which narrowed arteries reduce blood flow t...g for vascular disease, heart attack and stroke, a...
(Date:11/25/2009)...s could lead mothers to overlook needed care, stud...y News) -- A mother,s depression can worsen her ch...eir six-month study of 262 black mothers and their...re depressive symptoms had more frequent asthma sy...ssive symptoms had less frequent asthma symptoms. ...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2
...co, Inc. is,pleased to announce the introduction o...rapid point of care system utilizes a chemilumines...separation method that allows,this system to repor...ole blood sample., The PATHFAST system can handle...
..., Inc.,(the "Company") (Nasdaq: AFAM ) announced ...public offering price of $17.75 per share. In conn...as been granted an option to,purchase up to 337,50...fering, after underwriting discounts,and estimated...
...heterogeneous group and may not always be associat...he study of 145 triple negative breast cancers (i....gesterone receptor-negative and HER2-negative) in ...of the study. , Triple negative breast cancer i...
...l can detect prostate cancer and provide undistort...te tumor localization, according to a recent study...ersity in Columbus, OH. , The 3T MRI datasets we... an endorectal coil leads to deformation of the pr...
...confirming large bowel obstruction and identifying... recent study conducted by researchers at the Univ...There is very little published evidence regarding ...n clinical problem and plain films have been shown...
...h 3T MR-guided focused ultrasound (MRgFUS) is safe...t study conducted by researchers at Weill Cornell ...25% of women in the United States have clinically ...n developed in radiology, includingnon-invasive MR...
Other Medicine News:Health News:Almost Family Announces Pricing of 2,250,000 Common Shares 2Health News:CT useful and effective when diagnosing patients with large bowel obstruction 2
Lorenz 2.0 mm Flexible Titanium
Craniofix Titanium Clamp
...e Cfix cable fixation system is a flexible titaniu...crimping and address the surgeon's need for intrao... provides the surgeon with the ability to retighte...tting without the need for additional cables. Quic...
Grafton DBM Crunch
Medicine Products: